Related Experiment Video
Updated: Jun 5, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
Structural disruption of VKORC1 by resistance mutations reveals a conserved hydrophobic pattern essential for
Nolan Chatron1, Sionfoungo Daouda Soro2, Etienne Benoit2
1USC1233 RS2GP, INRAE, VetAgro Sup, University of Lyon, F-69280, Marcy l'Étoile, France. nolan.chatron@vetagro-sup.fr.
Abstract:
Vitamin K epoxide reductase (VKORC1) catalyzes the reduction of vitamin K epoxide to quinone and hydroquinone, a cofactor essential for the activation of clotting factors. Mutations in VKORC1 are known to confer resistance to vitamin K antagonists (VKAs) such as warfarin in both humans and rodents, yet the structural mechanisms underlying these resistances remain poorly understood. Using AlphaFold3-predicted structures, molecular docking and molecular dynamics simulations, we investigated the effects of four major resistance-causing mutations - W59G and L128S in Mus musculus, L120Q and Y139C in Rattus norvegicus - on VKORC1 structure and warfarin binding. Three mutations (W59G, L120Q and L128S) disrupted a hydrophobic cluster linking the ER luminal loop to transmembrane helices TM3-TM4, inducing and ER loop drift and altering helices orientation. These structural changes reduced warfarin affinity compared to the wild-type enzyme. In contrast, the Y139C mutation caused minimal perturbation and preserved wild-type binding energy, suggesting that it may confer resistance through a different mechanism. Collectively, six hydrophobic residues (V54, W59, L120, I123, L124, L128) were identified as a conserved structural pattern critical for VKORC1 stability and inhibitor sensitivity. This integrative structural study provides a mechanistic framework for understanding VKA resistance in VKORC1. It highlights a hydrophobic core essential for enzyme integrity and drug binding, offering a molecular basis for monitoring emerging mutations and for designing next-generation anticoagulants active against resistant VKORC1 variants.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Restarting Stalled Replication Forks

